| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
CampusGuard is focused on providing cybersecurity and compliance services for campus-based organizations like higher education, healthcare, and local government.
DG Technologies is a Farmington, MI-based company in the Software and Internet sector.
Ease.io provides the ultimate platform for simplifying digital transformation by offering intelligent automation tools for various processes. The companys products include chatbots, workflow automation, data analytics, and email campaign tools, allowi...
Cox2M is a new Internet of Things (IoT) business line within Cox Communications that provides complete asset tracking and monitoring solutions.